RUNX2 as a novel biomarker for early identification of patients progressing to advanced-stage mycosis fungoides.

ABSTRACT:

Introduction

The majority of patients with mycosis fungoides (MF) have an indolent disease course, but a substantial fraction (20-30%) of patients progress to advanced stages - usually with a grave prognosis. Early differentiation between indolent and aggressive types of MF is important for the choice of treatment regimen and monitoring of the individual patient. Good biomarkers are therefore desired.

Methods

Here, we used spatial transcriptomics on skin samples at time-of-diagnosis to enable prediction of patients who later progressed to advanced stages of MF. Formalin-fixed, paraffin-embedded skin biopsies at time of diagnosis from six patients with MF who progressed to advanced stages of disease within 4 months to 12 years after diagnosis, and nine patients who remained i

SUBMITTER: Danielsen M 

PROVIDER: S-EPMC11491341 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature